Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07303777 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
A Phase 2 study, sponsored by Atom Therapeutics Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07303777 is a Phase 2 study that is actively recruiting participants, run by Atom Therapeutics Co.. The registered enrollment target is 200 participants.
The verdict
NCT07303777, a Phase 2 study, is actively recruiting participants, sponsored by Atom Therapeutics Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.
Interventions
- DRUG Placebo
- DRUG ABP-745 Dose A
- DRUG ABP-745 Dose B
- DRUG ABP-745 Dose C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07303777
The ClinicalTrials.gov registry entry for NCT07303777 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07303777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07303777 about?
NCT07303777 is a clinical study titled "Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis". This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with AS...
What is the current status of trial NCT07303777?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-04-23. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07303777?
The interventions under investigation include: Placebo (DRUG), ABP-745 Dose A (DRUG), ABP-745 Dose B (DRUG), ABP-745 Dose C (DRUG).
Who is sponsoring clinical trial NCT07303777?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.